Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | USP2 | O75604 | 6/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | THPO | P40225 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | KCNK2 | O95069 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 8/20 | 0.98 |
| ▸ | MEN1 | O00255 | 7/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.98 |
| ▸ | RAD52 | P43351 | 3/20 | 0.98 |
| ▸ | GMNN | O75496 | 3/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.98 |
| ▸ | HTR1A | P08908 | 4/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E-Flupentixol SCHEMBL30596168 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| Z-Flupentixol SCHEMBL34200 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| E-Flupentixol SCHEMBL145726 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| E-Flupentixol SCHEMBL29598791 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| Z-Flupentixol SCHEMBL29361845 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| Z-Flupentixol SCHEMBL29620416 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| E-Flupentixol SCHEMBL11427109 | 0.99 | LMNA (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| Z-Flupentixol SCHEMBL719323 | 0.99 | LMNA (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| E-Flupentixol SCHEMBL1230220 | 0.99 | LMNA (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| Z-Flupentixol SCHEMBL1153162 | 0.99 | LMNA (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 826 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| WO-2024249914-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DYSTONIA | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | WO | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| CN-104513172-B | Acid amides alkaloid, preparation method and its medicinal usage containing trifluoromethyl | 天士力医药集团股份有限公司 | 2018-02-02 | — | — | CN | claimed |
| CN-105879031-A | Anticancer-drug-free composition realizing synergistic treatment on tumor | 北京大学 | 2016-08-24 | — | — | CN | claimed |
| US-20150099741-A1 | DIAGNOSING AND TREATING PATIENTS HAVING PSYCHIATRIC DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2015-04-09 | — | — | US | claimed |
| US-20140024638-A1 | TREATMENT OF COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA | TARGACEPT, INC. (US) | 2014-01-23 | — | — | US | claimed |
| EP-2665478-A1 | TREATMENT OF COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA | Targacept, Inc. (US) | 2013-11-27 | — | — | EP | claimed |
| US-20120201804-A1 | TISSUE KALLIKREIN FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER | SANOMUNE, INC. (CA) | 2012-08-09 | — | — | US | claimed |
| EP-1901726-A2 | COMPOSITION FOR TREATMENT OF PSYCHOSIS | EGIS GYOGYSZERGYAR (HU) | 2008-03-26 | — | — | EP | claimed |
| WO-2007148332-A1 | CATECHOLAMINE RECEPTOR MODULATION | YEDA RESAERCH AND DEVELOPMENT CO. LTD (IL) | 2007-12-27 | — | — | WO | claimed |
| WO-2007100913-A2 | GENES DIFFERENTIALLY EXPRESSED IN BIPOLAR DISORDER AND/OR SCHIZOPHRENIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-07 | — | — | WO | claimed |
| WO-2007007133-A2 | COMPOSITION FOR TREATMENT OF PSYCHOSIS | EGIS GYÓGYSZERGYÁR (HU) | 2007-01-18 | — | — | WO | claimed |
| CN-1726037-A | Treatment of headache with antipsychotics delivered by inhalation | ALEXZA MOLECULAR DELIVERY CORP (US) | 2006-01-25 | — | — | CN | claimed |
| CN-1226036-C | New therapeutic combinations of mirtazapine and antipsychotic agents, for treatment of prophylaxis of psychotic disorders | AKZO NOBEL NV (NL) | 2005-11-09 | — | — | CN | claimed |
| CN-1194672-C | Transdermal therapeutic system comprising effective psychotropic drugs | LOHMANN THERAPIE SYST LTS (DE) | 2005-03-30 | — | — | CN | claimed |
| CN-1348366-A | Transdermal therapeutic system with a highly effective neuroleptic agent | LOHMANN THERAPIE SYST LTS (DE) | 2002-05-08 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| CN-1251526-A | New therapeutic combinations of mirtazapine and antipsychotic agents, for treatment of prophylaxis of psychotic disorders | AKZO NOBEL NV (NL) | 2000-04-26 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | CYP3A4 2316/4885USP2 2613/4885SIGMAR1 554/4885 |
| US-20140024638-A1 | TREATMENT OF COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA | GRIN2C, GRIN2A, CHAT | CYP3A4 2747/4885USP2 2676/4885SIGMAR1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.